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Abstract
We identified pyrvinium pamoate, an old anthelminthic medicine, which preferentially inhibits anchorage-independent
growth of cancer cells over anchorage-dependent growth (,10 fold). It was also reported by others to have anti-tumor
activity in vivo and selective toxicity against cancer cells under glucose starvation in vitro, but with unknown mechanism.
Here, we provide evidence that pyrvinium suppresses the transcriptional activation of GRP78 and GRP94 induced by glucose
deprivation or 2-deoxyglucose (2DG, a glycolysis inhibitor), but not by tunicamycin or A23187. Other UPR pathways induced
by glucose starvation, e.g. XBP-1, ATF4, were also found suppressed by pyrvinium. Constitutive expression of GRP78 via
transgene partially protected cells from pyrvinium induced cell death under glucose starvation, suggesting that suppression
of the UPR is involved in pyrvinium mediated cytotoxicity under glucose starvation. Xenograft experiments showed rather
marginal overall anti-tumor activity for pyrvinium as a monotherapy. However, the combination of pyrvinium and
Doxorubicin demonstrated significantly enhanced efficacy in vivo, supporting a mechanistic treatment concept based on
tumor hypoglycemia and UPR.
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Introduction
Intratumoral heterogeneity is a common characteristic of solid
tumors [1]. As tumors progress and increase in size, cancer cells
located in certain parts of the tumor interior, are confronted with
hypoglycemia and hypoxia resulting from poor vascularization.
The hypoglycemic state of cancer cells within solid tumors are
usually further enhanced by the high energy demand met mainly
through enhanced glycolysis, or the Warburg effect. Cancer cells
under these stressful microenvironments become dormant and
resistant to radiation and chemotherapy, while actively dividing
cancer cells located at areas with sufficient blood supply, such as
outer layers of tumors, are killed by these treatments [2,3,4].
Therefore, combination therapies that simultaneously attack both
dormant hypoglycemic/hypoxic tumor cells and the proliferating
tumor cells of solid tumors are likely to be more effective in tumor
eradication than existing approaches.
Glucose-regulated protein 78 (GRP78) is a molecular chaperone
resident in the endoplasmic reticulum (ER) and plays a major role
in protecting cells from the apoptosis induced by ER stresses,
including glucose deprivation and hypoxia [5,6]. GRP78 and
GRP94 (HSP90a), normally expressed at relatively low levels, are
involved in facilitating folding, maturation and transportation of
nascent proteins [5]. Under ER stress, the accumulation of
unfolded or misfolded proteins in the ER triggers the unfolded
protein response (UPR), marked by drastic induction of a number
of UPR genes including GRP78 and GRP94 via transcriptional
activation [7]. The UPR maintains cell survival by limiting cell
proliferation and further accumulation of unfolded or misfolded
proteins in ER. The UPR is initiated from dissociation of ATF6,
PERK and IREa from GRP78 and subsequent transcriptional
activation of UPR target genes. Studies in the recent decade have
presented a complex network of signaling pathways activated by
the UPR following ER stress, involving key proteins e.g. GRP78,
GRP94, ATF-6, ATF-4, PERK, IREa, XBP-1 (Figure S1).
New evidence indicates that GRP78 plays a critical role in tumor
development, progression and resistance to chemotherapy [5,6].
Over-expressionofGRP78proteinwasfoundinanumberofhuman
tumors, e.g. aggressive breast cancer [8,9], gastric, cancer [10], lung
cancer [11], hepatocellularcarcinoma[12] and prostate cancer [13].
GRP78 is also known to interact with caspase 7 to protect cells from
apoptosis. Up-regulation of GRP78 appears to promote tumor
growth and the increase of malignancy and drug resistance. The
silencing of GRP78 by a small molecule was shown to be correlated
to apoptosis under ER stress [14,15]. Agents targeting the UPR
pathway may provide a new strategy against cancer.
Pyrvinium pamoate was an old anthelminthic medicine. Esumi
and colleagues recently reported that it was preferentially toxic to
glucose-starved cancer cells and had anti-cancer activity in a
hypovascular Panc-1 pancreatic cancer model, known to be
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anti-tumor activity has yet to be described. We recently
independently identified pyrvinium pamoate from a small
molecule compound library for preferential inhibiting anchor-
age-independent growth of cancer cells, and subsequently also
confirmed the reported preferential toxicity to hypoglycemic
cancer cells. We demonstrated that this effect can at least partially
be attributed to its inhibition of the UPR. We explored a novel
combination treatment scheme based on this mechanism of action
of pyrvinium to enhance anti-tumor activity.
Materials and Methods
Compounds
Pyrvinium phosphate salt was prepared by following sequential
steps: a) placing pyrvinium pamoate (ICN Pharmaceuticals, or
Valeant) in an Erlenmeyer flask with a magnetic stirring bar, b)
mixing with chloroform (Fisher), c) mixing with 95% ethanol
(Pharmaco), d) warming to 50uC with stir for 10 minute, e) adding
2% phosphoric acid (85% in 95% ethanol) to produce a
precipitate, f) adding ethyl acetate 2 minutes later, g) stirring for
20 minutes, h) collecting the solids by filtration followed by
washing with 2/1/1 ethyl acetate/chloroform /ethanol, i) drying
by air. The phosphate salt is freely soluble in water at 1 mg/ml,
giving an orange red solution. 2-deoxyglucose (2DG), A23187 and
tunicamycin were purchased from Sigma (Saint Louis, MO).
Cells
A549, SW480, DLD1, A2058, MCF7, SK-BR-3, PA-1, DU145,
PANC-1, IMR90, WI38, CCD-112CoN and HUVEC cells were
purchased from American Tissue Culture Collection (ATCC)
(Manassas, VA, USA) and cultured per recommendations.
HOP62, HOP92, NCI-H460, NCI-H522, HCT116, HT29, HS
578T, T47D, MDA-MB-231, MDA-MB-435, A2780, OVCAR-1,
OVCAR-4, OVCAR-5, OVCAR-8, SK-OV-3, Caov-3, UACC62,
UACC257, and PC3 cells were obtained from NCI (Frederick, MD,
USA) and were adapted to a single growth medium, RPMI 1640
(Invitrogen) supplemented with 10% FBS and 2 mM L-Glu. The
establishment of C.1 cells and culture conditions for both CHO and
C.1 cells were described previously[17]. All cells were maintained in
a humidified incubator with 5% CO2 at 37uC.
Plasmids, transfection and reporter gene assay
The pGL2-Grp78-169/LUC reporter gene was previously
described [18]. Panc-1 cells of 40% confluence in 96-well plate
format were co-transfected using Lipofectamine 2000 (Invitrogen) as
previously described [19], with the same total amount of DNA
containing pGL2-Grp78-169/LUC reporter gene plasmids and
pRL Renilla luciferase expression plasmids, adjusted with pcDNA3
empty vector. The cells were harvested 24–36 hours post-transfec-
tion. The firefly luciferase activity was measured and normalized
against Renilla luciferase activity using the Dual Luciferase kit
(Promega) per protocol provided by manufacturer [20].
Measurement of cell growth
Anchorage-dependent (liquid cell culture) and anchorage-
independent (soft agar culture) growth in 96-well plates were
previously described [19,21]. For growth under glucose depriva-
tion, the above anchorage-dependent growth in 96 well plates was
modified as follows: cell suspensions were plated in each well of a
96-well flat-bottom microtiter plate on day 1 and treated with
compounds at different concentrations in media with or without
glucose on day 2. The cells were allowed to grow for three days
before alamarBlueH staining (Trek Diagnostic Systems). Clono-
genicity of CHO and C.1 cells was determined by the procedures
described previously [17,22].
For measurement of growth of the Panc-1 cells expressing
exogenous GRP78, the cells in 96-well plates cells were co-
transfected using Lipofectamine 2000 (Invitrogen) as with total
same amount of DNA containing pcDNA-GRP78 and pGL2-
LUC reporter gene plasmids, adjusted with pcDNA3 empty
vector. The firefly luciferase activity was measured after
transfection for 24 hrs as a surrogate of cell growth [20].
Gene expression analysis
Real time RT-PCR used to quantitate mRNA levels in cells was
described previously with PCR primer and probe sequences as
follows: GRP78-probe: 59-/56 FAM/CAAACTTGTCCCC-
GAGCGACGAGA /BHQ1/-39, GRP78-forward primer: 59-
TGGCAGGAGAGAGTTACAGTCG, GRP78-reverse primer:
59- GCCCTGCAGTCTCTCCCAC-39); GRP94-probe: 59-/
56FAM/ TGTTTGACGAATA TGGATCTAAAAAGAGC-
GATTACAT/3BHQ-1/39, GRP94-forward primer: 59- CCCA-
CATCTGCTCCACGTG; GRP94-reverse primer: 59-
CACGGCGCACATAG AGCTT -39); ATF4-probe: 59/
56FAM/TTGGTCAGTCCCT CCAACAACAGC AAG /
3BHQ-1/39, ATF4-forward primer: 59- TGGCTGGCTGT
GGATGG; ATF4-reverse primer: 59-TCCCGGAGAAGG-
CATCCT-39); XBP1-probe: 59-/56FAM/ CCCAGTTG
TCACCCCTCCAGAACATCTC/3BHQ-1/39, XBP1-forward
primer: 59- ACCTCTGCAGCAGGTGCAG; XBP1-reverse
primer: 59-AATACCGCCAGAATCCA TGG -39). XBP1-spliced
-probe: 59-/56FAM/ CCCAGTTGTCACCCCTCCAGAACAT
CTC /3BHQ-1/39, XBP1-spliced -forward primer: 59-AC-
CTCTGCAGCAGGTGCAG-39; XBP1-spliced -reverse primer:
59-AATACCGCCAGAATCCATGG -39).
Western blot analysis procedure was also previously de-
scribed[20,21,23]. Monoclonal antibody against KDEL and
polyclonal antibody for HA tag were purchased from Stressgen
Bioreagents (Ann Arbor, MI) and US Biological (Swampscott,
Massachusetts) respectively. Polyclonal antibodies against ATF4,
Erk2, phospho-Akt and Akt were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA).
Xenograft models
The establishment of human xenograft tumor was previously
described [23]. Briefly, female athymic nude mice (nu/nu) (4–6
weeks old) were purchased from Simonsen Laboratory, Inc.
(Gilroy, CA). The animal use and care protocol was approved by
Perry Scientific’s Animal Care and Use Committee (ACUC) and
all procedures were conducted according to the guidelines of
NIH/Department of Human and Health Services. Athymic mice
were inoculated (s.c.) with 5610
6 cancer cells in PBS on the
athymic mouse flanking site. Animals were randomly divided into
treatment and control groups with similar average tumor sizes.
For HCT116 and AsPC-1 xenograft models, animals in the
treatment group received pyrvinium pamoate daily at 10 mg/kg
via oral administration (p.o.) and 0.5 mg/kg via intraperitoneal (i.p.)
administration, 6 times weekly for five weeks respectively. For PC3
cancer model, animals in the first group were treated with
pyrvinium pamoate daily at 10 mg/kg via oral dosing, 6 times
weekly for five weeks. The second group was administrated with
doxorubicin i.p. at 4 mg/kg, once per week for two weeks. The
third group was treated with both pyrvinium pamoate and
doxorubicin as described above. The control groups were dosed
with 5% dextrose (vehicle) with the same schedule as the treatment
group. Tumor volumes were manually measured and calculated as
previously reported [23]. The significance of variability between
Pyrvinium UPR Targeting
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determined by ANOVA and independent Student’s t-test. The
level of statistical significance was set at 0.05.
Results
Pyrvinium broadly inhibits anchorage-independent
growth of cancer cells
Anchorage-independent growth of cancer cells is a hallmark of
cell transformation. In an effort to identify compounds with
selective anti-cancer activity, we screened a small compound
library composed of drugs, drug-like and natural compounds,
using 96-well format soft-agar (SA) assay, an anchorage-indepen-
dent growth assay we recently developed [21]. Three NCI
prototype cancer cell lines, PC3 prostate cancer, MCF-7 breast
cancer and NCI-H460 NSCL, were used in our initial screen.
Pyrvinium pamoate was identified among the hits with preferential
inhibitory activity for anchorage-independent growth (Figure 1B)
over anchorage-dependent growth (Figure 1A) measured by liquid
culture (LIQ) growth. We then further examined pyrvinium
pamoate against a large panel of cancer cells and confirmed this
property in a majority of cancer cell lines tested (Table S1,
Figure 1). The higher potency of pyrvinium pamoate against
cancer cells in anchorage-independent growth suggests a possible
desirable therapeutic index as cancer treatment.
During the course of our study, Esumi and colleagues reported
anti-tumor activity of pyrvinium pamoate in human pancreatic
cancer Panc-1 xenograft models [16]. More interestingly, they also
described that pyrvinium pamoate sensitized cancer cells to glucose
deprivation (IC50,0.1 mM) or 3-dimensional growth (spheroid),
both subsequently confirmed by us. Our soft agar growth assay may
resemble spheroid growth since both are 3-dimensional without
attaching to culture dish, although the interpretation for the
observed sensitivity for spheroid growth by these authors was due
to glucose deprivation inside the spheroid itself.
Pyrvinium pamoate is insoluble in water (,1 mM), thus not a
practical salt form for in vivo pharmacological evaluation (see
below). We created several new pyrvinium salts including
phosphate and sulfate salts, with significantly increased water
solubility (data not shown). These new salts were retested in the
same in vitro assays and were confirmed to have the same
phenotypes as seen for pyrvinium pamoate, verifying that the
pyrvinium moiety, instead of pamoate, is responsible for the
observed phenotypes since pamoate alone did not show any
observable effect (Figure S2). Pyrvinium phosphate was used in all
subsequent in vitro experiments, unless specified otherwise.
Pyrvinium specifically suppresses the up-regulation of
GRP78 and GRP94 induced by glycolytic inhibition
Esumi and colleagues reported that pyrvinium pamoate
dephosphorylated Akt in Panc-1 cells only when glucose was
deprived, which was correlated to the observed preferential
cytotoxicity. This hinted a possible role of Akt in the pyrvinium
pamoate action [16]. To verify whether this association generally
exists in cancer cells, we compared Akt phosphorylation during
glucose starvation and pyrvinium treatment in several additional
human cancer cells. Although the preferential cytotoxcity
remained in all the tested cells, the phosphorylation profiles of
Akt varied greatly upon glucose deprivation and pyrvinium
treatment as shown in Table 1 and Figure 2. This suggests that
Akt is not a common mechanism for the observed biological effect
of pyrvinium in many these cancer cells, although we cannot rule
out the role of Akt in some of cells, e.g. panc-1. There must be
other pathways involved in the pyrvinium actions.
GRP78 and GRP94 are two ER resident stress response
chaperones that are transcriptionally induced during glucose
deprivation as part of the UPR, which protects cells from apoptosis
under a variety of stress conditions [5,24]. We were therefore
interested in whether pyrvinium affects GRP78 and GRP94
induction caused by glucose deprivation. Figures 3A and 3B shows
the induction of GRP78 and GRP94 mRNA levels in Panc-1 cells,
as measured by Taqman real-time RT-PCR for 6 hours (3 and 2
fold respectively) and 24 hours (11 and 5 fold respectively) of
glucose starvation. Interestingly, these inductions were completely
suppressed by pyrvinium treatments at 0.1 and 0.3 mM (Figure 3A
and 3B), the concentrations causing cytotoxicity. Since there was
no apparent cell death measured by alamarBlue assay for the
6 hour treatment, the observed suppression of the GRP78 and
Figure 1. Sensitivity of different cancer cells to pyrvinium pamoate under anchorage -dependent and -independent conditions.
Cells were seeded into each well of a 96-well plate in liquid culture (A) and soft agar culture (B) at 1e3/well for one day. Cells were treated with
pyrvinium pamoate at indicated concentrations and cell growth in culture was measured after incubation at 37uC for 3 days (A) and 7 days by alamar
Blue staining with excitation at 530625 nm and emission at 590635 nm (B). Error bars: standard deviations (SD).
doi:10.1371/journal.pone.0003951.g001
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similar an inhibitory effect was also reflected at protein levels as
shown by immunoblot analysis (Figure 3C). Importantly, this
suppression was also seen in all the tested cells including PC3
human prostate cancer, 143b osterosarcoma cell lines (Figure 3D)
and CHO cells (Figure 4), suggesting an ubiquitous effect of
pyrvinium on the UPR
2-deoxyglucose (2DG) is a glucose analog, a glycolysis inhibitor
and also a transcriptional activator of GRP78 or the UPR
response [15], as seen in glucose starvation. We next investigated
whether pyrvinium also suppressed GPR78 transcriptional
activation by 2DG in Panc-1 cells. We found that the induction
of GRP78 and GRP94 mRNA by 2DG was completely suppressed
by pyvinium, similar to that seen in glucose deprivation
(Figure 3E). There are other compounds also activating the
UPR, which are all associated with the up-regulation of GRP78,
including tunicamycin, an antibiotic inhibiting the first step of
glycoprotein synthesis. Interestingly, pyrvinium did not suppress
the GPR78/94 induction by tunicamycin (Figure 3F), demon-
strating that the pyrvinium effect is limited to specific stress
conditions of hypoglycemia and glycolysis inhibition.
We were also interested in whether down-regulation of the
steady state levels of GRP78 mRNA/proteins resulted from
transcriptional suppression, a characteristic UPR regulation. To
this end, a reporter system for GRP78 transcription, pGL2-Grp78-
169/LUC, was used. This system contains a GRP78 promoter
driven luciferase reporter gene. The promoter harbors the cis-
acting ER stress response element (ERSE) that is required for ER
stress-mediated transcriptional activation [18,25]. Since UPR
induction can affect general protein synthesis including reporter
protein synthesis, pGL2-Grp78-169/LUC was co-transfected
along with a renilla luciferase gene driven by constitutive promoter
as an internal control, which ensures that the observed effect is
related to UPR-specific transcriptional regulation, rather than the
changes in general protein synthesis or the variation in transfection
efficiency. As shown in Figure 3G, Panc-1 cells transfected with
pGL2-Grp78-169-LUC displayed induced luciferase activity by
the treatments of 2DG, tunicamycin or calcium ionophore
A23187 (another agent known to induce GRP78 [26]) (2,3 fold
over untreated) as reflected by the ratio of firefly to renilla
luciferase activities. These promoter reporter activations are
similar to the induced endogenous GRP78 mRNA levels, which
confirms the transcriptional induction by these ER stresses.
Pyrvinium selectively suppressed 2DG-induced, but not tunica-
mycin or A23187 induced GRP78 promoter reporter readouts in a
dose-dependent fashion, confirming the transcriptional suppres-
sion of GRP78 by pyrvinium, which is specific to 2DG or glucose
deprivation. These results suggest that pyrvinium likely targets the
UPR pathway upstream of GRP78.
Pyrvinium mediated GRP78 suppression contributes to
the enhanced cytotoxicity under hypoglycemic
conditions
Since GPR78/94 induction constitutes one of the key pro-
survival mechanisms of cancer cells in response to glucose
deprivation, pyrvinium-mediated suppression of GRP78 and
GRP94 expression may counter this survival mechanism and
resulted in rapid cell death. This assumption was indeed supported
by the observed correlation between the suppressed expression of
GRP78 and GRP94 by pyrvinium and cytotoxicity. As shown in
Figure 3H, significantly increased cell death was observed when
Panc-1 cells were treated with pyrvinium in combination with
glucose starvation or 2DG, but not with tunicamycin and A23187.
In order to verify that the suppression of GRP78 by pyrivinium
indeed contributed to the enhanced cytotoxicity by pyrvinium in
the presence of 2DG, we tested whether constitutively expression
of GRP78 can reverse the pyrvinium induced cell death in the
presence of 2DG. We previously described a GRP78 transgene
expressing cell line C.1, a CHO line constitutively expressing
exogenous GRP78 [17]. We tested C.1 by clonogenic assay in the
presence of 2DG in parallel to the parental CHO cells. The result
showed that C.1 cells, with exogenously expressed GRP78 that
could not be down-regulated by pyrvinium (Figure 4A), were
significantly more resistant to the treatments by 2DG, or by the
combination of pyrvinium and 2DG, as compared to the parental
CHO cells (Figure 4B and 4C). Similar results were also observed
a cell proliferation assay in 96 well format (Figure 4D).
Although CHO cells, the parental cell line of C.1, also show the
properties of preferential cytotoxicity and GRP78 down regulation
by pyrivinium under glycolytic suppression as seen in Panc-1 and
Figure 2. Effect of pyrvinium on Akt phosphorylation. Cells in culture media with or without glucose were treated with pyrvinium phosphate
(pyrvinium-p) at 0.1 uM for 2 hrs. The phosphorylation levels of Akt were measured by western blot using anti-phospho-Akt and anti-Akt antibodies.
doi:10.1371/journal.pone.0003951.g002
Table 1. Akt dephosphorylation by pyvinium phosphate in
various tumor cell lines under glucose starvation.
Cancer cell lines Reduction of Phospho-Akt level
AsPC-1 Yes
PANC-1 Yes
A549 Yes
HCT116 No
PC3 No
JHMG No
Hop62 No
H460 No
Note: These results are summary of Western blot analysis of cells cultured in
growth media+/2glucose and treated with pyrvinium (0.1 mM, 2 hrs.), using
anti-phospho-Akt and anti-Akt antibodies.
doi:10.1371/journal.pone.0003951.t001
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PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e3951Figure 3. Pyrvinium suppresses GRP78 and GRP94 expression. Panel 3A, 3B, 3D 3E and 3F: Quantitative real-time RT-PCR analysis. Panc-1
cells (A, B, E and F) and PC3 and 143b cells (D), cultured in growth media with or without glucose (A and B), 2DG (D and E) and tunicamycin (F), were
treated with pyrvinium phosphate (pyrvinium-p) for 6 hrs (A D and E) and 24 hrs (B and F). Total RNA was harvested and subjected to Taqman real-
time PCR analysis for GRP78 and GRP94. Panel 3C: Western blot analysis. Panc-1 cells in growth media with or without glucose were treated with
Pyrvinium UPR Targeting
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argue that the rescued phenotype observed in C.1 cells may not be
necessarily relevant to that in Panc-1 cells. To confirm this
mechanism in panc-1 cells, we conducted a similar transient
exogenous GRP78 over-expression experiment based on a
luciferase-based survival assay that we previously developed [20].
This assay aimed to readily measure the effect of a gene on cell
proliferation/survival using a transient transfection with enhanced
signal/noise ratio. In this experiment, we co-transfected Panc-1
cells with the GRP78 expression construct and a SV40 promoter-
driven luciferase expression cassette followed by measuring the
luciferase activity as a surrogate marker for cell proliferation/
survival of the cotransfected cells. Figure 4E demonstrates that
ecotopic expression of GRP78 indeed resulted in significant
resistance of cells to pyrvinium under glucose deprivation reflected
by the higher luciferase activity than cells without ectopic
expression of GRP78. Together, all these observations suggest
that GPR78 down-regulation by pyrvinium indeed causally, at
least in partial, contributes to the pyrvinium action leading to the
enhanced cytotoxcity under glucose deprivation.
Figure 4. Over-expression of GRP78 protects cells from pyrvinium-induced cell death. A: Quantitative real-time RT-PCR analysis. CHO and
C.1 cells cultured in growth media with or without 2DG were treated with pyrvinium phosphate (pyrvinium-p) for 6 hrs. Total RNA was harvested and
subjected to Taqman real-time PCR analysis for GRP78. B and C: Clonogenicity assay. CHO and C.1 cells were seeded on day 1. The cultures were
treated on day 3 with 2DG (10 mM), pyrvinium-p (0.1 mM) or combination of 2DG and pyrvinium-p for another 18 hrs and continued to culture for 2
weeks. The colonies were quantitated. D: alamarBlue readout of cell proliferation (3 days in 96 well plates) as described in figure 1. The SD of triplicate
samples is shown.
doi:10.1371/journal.pone.0003951.g004
pyrvinium-p and tunicamycin for 24 hrs. The cell lysates were harvested for western blot using anti-KDEL antibody for detection of GRP78 and GRP94,
Erk2 (internal control). Panel 3G: reporter gene assay for detection of GRP78 promoter. Panc-1 cells were co-transfected with GRP78-169/LUC and
Renilla luciferase genes. The cells were treated with pyrvinium-p in combination with 2DG, tunicamycin or A23187 for 24 hrs. The firefly luciferase
activity was measured and normalized against Renilla luiciferase activity using the dual luciferase kit. All of the transfections were performed in
duplicates or triplicates. Panel 3H: cell growth assay. Panc-1 cells were treated with pyrvinium-p in combination with glucose starvation, 2DG,
tunicamycin or A23187 for 72 hrs and cell proliferation was measured by alamarBlue staining (3 days in 96 well plates). Error bars: SD.
doi:10.1371/journal.pone.0003951.g003
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Several factors are known to be responsible for ER stress-
mediated transcriptional activation of GRP78, including the
alternatively spliced XBP-1 (sXBP-1) and activated ATF6 [27].
We examined the effect of pyrvinium on XBP-1 splicing following
glucose starvation to further understand its mechanism of action.
Figure 5A shows that pyrvinium significantly down-regulates the
induction of sXBP-1 mRNA by glucose deprivation, suggesting
that XBP-1 is the more proximal target of pyrvinium than GRP78.
Because the transcription of XBP-1 is also under ERSE control
similar to GRP78, we examined the effect of pyrvinium on the
expression of the total XBP-1 mRNA. As expected, pyrvinum also
significantly suppressed the XBP-1 up-regulation (mRNA) by
glucose starvation (Figure 5A). These results further support the
notion that pyrvinium inhibits ERSE-dependent transcription
mediated by glucose deprivation.
Pyrvinium suppresses ATF-4 transcriptional activation by
glucose starvation
ATF-4 is a cAMP response element-binding transcription factor
(CREB) and promotes cell survival by activating certain gene
transcription including those involved in the stress response,
including the GRP78 promoter [28]. Previous data indicated that
ATF-4 was activated by an alternative translational initiation in
response to a general inhibition of protein synthesis as part of the
UPR [29,30], however, so far there has been no report on ATF-4
mRNA induction as part of UPR. However, when we investigated
whether ATF-4transcription is affected bypyrvinium,we found that
2DG or glucose starvation clearly up-regulated ATF4 at both
protein(Figure 5B)and mRNA(Figure5C) levels. The data provides
evidence for the first time that ATF4 mRNA is also up-regulated by
glucosestarvation and tunicamycin likely as partofUPR,although it
is still unclear whether this was due to increased transcription or
mRNA stability. Further studies on ATF4 transcriptional regulation
will give new insights into the UPR pathways.
With this new information of ATF-4 up-regulation by glucose
deprivation, we next asked whether this up-regulation can also be
suppressed by pyrvinium. We demonstrated that the mRNA and
protein induction was completely suppressed by pyrvinium
treatment. In contrast, no suppression was observed for tunica-
mycin-mediated ATF4 induction. These results again provided
evidence that pyrvinium also affects the UPR by acting on the
PERK pathway, another major UPR pathway. It is noteworthy
that pyrvinium actually up-regulates ATF4 protein in the presence
of glucose (Figure 5B), contrasting to that seen in the absence of
glucose. Because ATF4 expression could be induced by other
stresses unrelated to the UPR [31], pyrvinium may also trigger
other stress pathways when glucose is available.
Anti-tumor activity of pyrvinium alone is limited
On the basis of the higher potency against cancer cells deprived
of glucose, Esumi and colleagues reasoned that pyrvinium
pamoate could potentially be effective against solid tumors, since
parts of solid tumors are usually deprived of glucose, oxygen and
other nutrients. They tested this hypothesis by assessing anti-tumor
activity in a Panc-1 pancreatic cancer xenograft model, since
pancreatic cancers are poorly vascularized (with less access to
glucose) and insensitive to hypoglycemia, as compared to other
solid tumors. They confirmed their hypothesis by demonstrating
the Panc-1 xengraft tumor response to oral administration of
pyrvinium pamoate [16]. In order to assess breadth of pyrvinium
anti-solid tumor activity, we tested pyrvinium pamoate and other
soluble pyrvinium salts in several additional xenograft models,
either via oral administration or i.p. injection. We tested systemic
delivery of soluble pyrvinium salt to enhance anti-tumor activity
by overcoming the limitation of oral absorption. Overall, our data
showed rather marginal tumor responses to pyrvinium treatment
(see Table S3, Figure 6A and 6B), with some responses seen in
HCT116 colon cancer and A2780 ovarian cancer (early staged
tumors) models, but little in PC3 prostate cancer, AsPC1
pancreatic cancer, and A549 NSCL tumor models. Furthermore,
when i.p. dosed with the soluble salts, the dose-limiting toxicity was
clearly evident, contrasting to the safe oral administration of
pyrvinium regardless of salt form and confirming the poor oral
absorption of pyrvinium.
Combination therapy of pyrvinium with doxorubicin is
significantly more effective than monotherapy
The weak anti-tumor activity of pyrvinium could be explained
by the following possibilities: first, attacking the hypoglycemic
tumor areas is simply insufficient to mount an effective overall
anti-cancer treatment, similar to those seen in many anti-
angiogenic monotherapies; second, glucose levels in tumors are
still too high to render pyrvinium effective. These two putative
limitations can potentially be overcome by combination therapy
Figure 5. Pyrvinium suppresses XBP-1s, XBP-1 and ATF4
expression. 5A: Panc-1 cells cultured (6glucose) were treated with
pyrvinium-p for 6 hrs. Taqman real-time PCR was conducted using
primers and probes against XBP-1 (black bar) and XBP-1s (open bar). 5B:
Western-blot analysis of the Panc-1 cells treated with 2DG, tunicamycin
and pyrvinium for 24 hrs using anti-ATF4 and Erk2 antibodies (a
representative of 3 independent experiments). 5C: Quantitative real-
time RT-PCR analysis. Panc-1 cells cultured with or without glucose and
pyrvinium treatment (24 hours) and the total RNA was harvested for
detection of ATF4 mRNA levels. Error bars: SD.
doi:10.1371/journal.pone.0003951.g005
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cancer cells in normal glycermic areas (e.g. exterior) and/or further
deprive glucose levels in solid tumor via shutting down blood flow,
thus broadening therapeutic window. We therefore evaluated the
combination therapy of pyrvinium with a conventional chemo-
therapy agent doxorubicin for being potent against dividing cancer
cells and their anti-angiogenic effects.
A PC3 xenograft cancer model was employed for the
doxorubicin combination treatment since PC3 tumors treated by
doxorubicin had been well documented with detailed dosing,
toxicity and efficacy information [32], which served as guidance
for the first combination experimental design. In addition, both
doxorubicin and pyrvinium are rather ineffective against PC3
xenograft tumor growth, thus an idea model for testing
combination. We established 50 PC3 tumor xenografts in athymic
mice and allowed the tumors to reach average volumes of
150 mm
3. The tumor-bearing animals were then divided into four
treatment groups: group 1 (PBS daily oral (p.o.) dosing), group 2
(4 mg/kg doxorubicin once a week i.p. dosing for 2 week), group 3
(10 mg/kg pyrvinium daily oral (p.o.) dosing), group 4 (4 mg/kg
doxorubicin once a week i.p. dosing for 2 weeks with 10 mg/kg
pyrvinium daily oral (p.o.) dosing). The tumor responses to these
treatments are shown in Figure 6E. While little response was seen
for either single agent treatments of doxorubicin and pyrvinium
Figure 6. Anti-tumor effects of pyrvinium monotherapy or combination therapy with doxorubicin. 6A. 6B, 6C and 6D: HCT116 (A and B)
and AsPC-1 (C and D) models. Pyrvinium pamoate was administrated either orally (p.o. 10 mg/kg) or i.p. (0.5 mg/kg) 6 times/week. 6E and 6F:
pyrvinium pamoate combination therapy in PC3 model. Pyrvinium (p.o. 10 mg/kg 6 times/week), and/or Doxorubicin (i.p. 4 mg/kg, weekly for 2
weeks) were administrated. 10 or 12 mice in each group (n=10 or 12) were used for all the experiments. Error bars: standard error (SE); *: p,0.05.
doi:10.1371/journal.pone.0003951.g006
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as compared to control (p,0.05). This demonstrated the likely
synergistic inhibition of PC3 tumor growth by the pyrvinium and
doxorubicin combination in vivo. General toxicity was evaluated on
the basis of changes in animal body weight (Figure 6B, 6D and 6F).
Among all the treated groups, only animals that received
doxorubicin only or the combination therapy showed the similar
body weight loss (,20%, Figure 6F), suggesting that the observed
toxicity is due to doxorubicin but not pyrvinium.
Discussion
Esumi and colleagues proposed a possible role for Akt in the
action of pyrvinium pamoate, since pyrvinium inhibits Akt
phosphorylation in glucose deprived Panc-1 cells [16]. However,
severalobservationssuggestthatthispathwaymaynot be essentialor
universal. First, LY294002, a PI3K inhibitor, did not abolish Panc-1
celltolerancetoglucosedeprivationeventhoughitinactivatedAktas
shown by the same group [33] and by our own data (not shown).
Second,pyrvinium pamoate dephosphorylated Aktthatwas induced
by glucose starvation, but failed to inactivate Akt activity induced by
insulin [16]. Third, diverse cancer cell lines exhibited highly varied
Akt expression profiles with pyrvinium treatment under glucose
deprivation, which are not correlated to the consistent survival
phenotypes (Figure 2 and Table 1). Therefore, while Akt might have
been involved in specific cancer cell lines, other additional
mechanisms are also likely involved in pyrvinium action.
Our data demonstrated that pyrvinium specifically suppressed
the transcriptional induction of UPR activators by glucose
deprivation, including GRP78, XBP1 and ATF4. These activities
are consistent in all the tested cells and correlated with the selective
toxicity of pyrvinium to glucose-deprived cells, contrasting to that
of Akt, suggesting a possible novel mechanism for pyrvinium. The
fact that over-expression of exogenous GRP78 increased the
resistance to pyrvinium under glucose deprivation confirmed the
causal link between UPR suppression and pyrvinium action.
The UPR is a protective mechanism by tumor cells adapting to
stressful microenviroments, e.g. hypoxia, nutrient deprivations and
the exposure to genotoxic agents. Shutting-down UPR induction
sensitizes cells to these stresses. Versipelostatin, a small molecule,
was recently reported to selectively suppress UPR induction by
glucose deprivation ([15] also see Figure S3 and Table S4). It also
has anti-tumor activity in xenograft tumor models, further
supporting the notion that suppressing glucose starvation mediated
UPR could be a potential novel anticancer strategy. Pyrvinium
displays some similarity to that of versipelostain (Table S4). Both
compounds seem to target upstream pathways of GRP78, but
likely via different molecular targets. The difference is reflected by
the facts that first, versipelostain mainly causes apoptosis to glucose
deprived cancer cells [14,15], while pyrvinium also triggers
necrosis [16] with significantly higher potency (IC50: 0.03–
0.1 mM vs. 1–3 mM) in cytotoxicity and inhibition of GRP78
(10,100 fold); second, there absolutely is no structural similarity
between the two (Figure S3); third, while UPR has been
demonstrated to be causally linked to pyrvinium action, the
similar causal role of UPR for versaipelostain action has yet been
reported.
The existing chemotherapies are limited by two major factors:
narrow therapeutic window and rapid development of drug
resistance. The narrow therapeutic window is largely reflected by
the low selectivity against cancerous tissues versus normal tissues.
Pyrvinium has unique selectivity against hypoglycemic tumor
tissues vs. normal tissues under normal glucose condition. This
selectivity likely results from its impacts on the transformation
pathways relevant to energy metabolism, and can thus be
exploited to increase the therapeutic window. The development
of drug resistance is complex and involves diverse mechanisms,
one of which, in solid tumor therapy, is hypoxia/ hypoglycemia in
the tumor interior resulting from hypovasculation [34]. An agent,
such as pyrvinium, specifically targeting the drug resistant and
dormant solid tumor interior will have particular therapeutic
value.
Our attempted pyrvinium combination therapy with toxic
agents/anti-angiogenic agent (Doxorubicin) was proven to be
effective, supporting our assumed effective solid tumor treatment
mechanism based on the simultaneous targeting of hypoglycemic
areas and normal glycermic areas. One of the most serious
problems confronting current chemotherapies is their undesirable
general toxicity, e.g. the life-dose limitation of Doxorubicin [35].
The enhancement of efficacy (Doxorubicin), as shown in this
study, suggests that the combination treatment may have safer and
more practical advantages over the single chemotherapy in the
current clinical settings.
Supporting Information
Figure S1 ER stress-mediated UPR signal pathways. Red color
represents targets or pathways affected by both pyrvinium and
versipelostatin.
Found at: doi:10.1371/journal.pone.0003951.s001 (4.51 MB TIF)
Figure S2 Inhibition of cell growth by different pyrvinium salts.
Cells were seeded into each well of a 96-well plate in liquid culture
with or without glucose at 1e3/well for one day. Cells were treated
with pyrvinium at indicated concentrations and cell growth in
culture was measured after incubation at 37uC for 3 days by
alamarBlue staining. Error bars: standard deviations (SD).
Found at: doi:10.1371/journal.pone.0003951.s002 (2.78 MB TIF)
Figure S3 Structures of pyrvinium and versipelostatin.
Found at: doi:10.1371/journal.pone.0003951.s003 (2.31 MB TIF)
Table S1 Pyrvinium phosphate preferentially inhibits cancer cell
anchorage-independent growth over anchorage-dependent growth
Found at: doi:10.1371/journal.pone.0003951.s004 (0.06 MB
DOC)
Table S2 Pyrvinium phosphate preferentially inhibits cancer cell
growth deprived with glucose
Found at: doi:10.1371/journal.pone.0003951.s005 (0.03 MB
DOC)
Table S3 A Summary of tumor responses to pyrvinium in
xenograft tumor models
Found at: doi:10.1371/journal.pone.0003951.s006 (0.05 MB
DOC)
Table S4 Comparison of pyrvinium and VST-1 effects on UPR
Found at: doi:10.1371/journal.pone.0003951.s007 (0.03 MB
DOC)
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